Holen Sie sich die Stockscreener-App
4.01
13.60%
0.48
Adc Therapeutics Sa Aktie (ADCT) Neueste Nachrichten
ADC Therapeutics reports promising LOTIS-7 trial results - MSN
Is ADC Therapeutics SA a good long term investmentCup and Handle Formations & Discover High-Return Stocks Before They Boom - earlytimes.in
Will Fed Rate Hikes Affect Voltaire Leasing Finance Limited Stocks OutlookPrice Volatility Patterns & Target Triple-Digit Stock Opportunities - earlytimes.in
ADC Therapeutics Reports Promising LOTIS-7 Trial Results - TipRanks
ADC Therapeutics Updates LOTIS-7 Trial Data - TradingView
[8-K] ADC Therapeutics SA Reports Material Event | ADCT SEC FilingForm 8-K - Stock Titan
Is ADC Therapeutics SA Common Shares stock attractive post correction2025 Institutional Moves & Growth Focused Investment Plans - Newser
Is ADC Therapeutics SA stock oversold or undervalued2025 Market WrapUp & Scalable Portfolio Growth Ideas - Newser
What momentum indicators show for ADC Therapeutics SA stockShare Buyback & Accurate Entry and Exit Point Alerts - Newser
Will ADC Therapeutics SA stock benefit from commodity pricesQuarterly Trade Summary & Daily Entry Point Alerts - Newser
How forex fluctuations impact ADC Therapeutics SA Common Shares stockPortfolio Performance Report & Reliable Intraday Trade Plans - Newser
Will ADC Therapeutics SA Common Shares stock boost dividends further2025 Analyst Calls & Capital Protection Trading Alerts - Newser
Can ADC Therapeutics SA stock deliver surprise earnings beatOptions Play & Long-Term Investment Growth Plans - Newser
Why Is ADC Therapeutics Plunging Today - Sahm
ADC Therapeutics updates data from Phase 1b trial of Zynlonta in lymphoma - Yahoo Finance
ADC Therapeutics (NYSE:ADCT) Trading Up 6.5%Should You Buy? - MarketBeat
ADC Therapeutics stock falls after LOTIS-7 trial update By Investing.com - Investing.com Canada
ADC Therapeutics stock falls after LOTIS-7 trial update - Investing.com India
Crude Oil Gains 1%; Macy's Reports Strong Q3 Results - Benzinga
ZYNLONTA-glofitamab combo shows 90% response rate in lymphoma trial By Investing.com - Investing.com Nigeria
ADC Therapeutics SA (ADCT) Discusses Updated Results From LOTIS-7 Trial Evaluating ZYNLONTA Plus Glofitamab in Relapsed or Refractory DLBCLSlideshow (NYSE:ADCT) 2025-12-03 - Seeking Alpha
ADCT: LOTIS-7: Zynlonta plus glofitamab delivers high, durable CR rates and manageable safety in DLBCL - TradingView
ADC Therapeutics : (ADCT Webcast Presentation 120225) - marketscreener.com
ADC Therapeutics Says Updated Data for Drug Supports Potential Best-in-Class Regimen in Lymphoma Patients - marketscreener.com
ADCT: ZYNLONTA plus glofitamab delivers high response rates and manageable safety in r/r LBCL - TradingView
ZYNLONTA-glofitamab combo shows 90% response rate in lymphoma trial - Investing.com
ADC Therapeutics announces updated data from Lotis-7 phase 1b clinical trial of Zynlonta - marketscreener.com
Adc Therapeutics Announces Updated Data From Lotis-7 Phase 1B Clinical Trial Of Zynlonta - TradingView
ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma - Fidelity
ADCT: LOTIS-7 Phase 1b trial update for ZYNLONTA plus glofitamab in r/r DLBCL set for Dec 3, 2025 - TradingView
ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial - BioSpace
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - 富途牛牛
Is ADC Therapeutics (ADCT) Outperforming Other Medical Stocks This Year? - sharewise.com
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire) - Aktiellt
H.C. Wainwright Lowers ADC Therapeutics (ADCT) PT to $7 Following $60M Private Placement - MSN
Can ADC Therapeutics SA Common Shares stock sustain margin levelsJuly 2025 Recap & Fast Moving Market Watchlists - BỘ NỘI VỤ
ADC Therapeutics to Present at the Cantor Global Healthcare Conference 2025 (PR Newswire) - Aktiellt
ADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update (PR Newswire) - Aktiellt
Adc Therapeutics SA (ADCT) is looking forward to a strong quarter - Setenews
ADC Therapeutics Makes Grant to New Employee Under Inducement Plan (PR Newswire) - Aktiellt
ADC Therapeutics SA (NYSE:ADCT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
ADC Therapeutics SA (NYSE:ADCT) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
How ADC Therapeutics SA Common Shares stock expands through international markets2025 Momentum Check & Expert Curated Trade Setup Alerts - newser.com
How cyclical is ADC Therapeutics SA Common Shares stock compared to rivalsJuly 2025 Price Swings & Weekly Hot Stock Watchlists - newser.com
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):